AstraZeneca’s oral relaxin agonist showed improvement in cardiac function for some patients in a mid-stage trial, though the overall results were described as a partial success. The study’s mixed outcome points to a need for tighter patient selection or dosing optimization ahead of any next-step development. For investors and clinicians, the readout matters because relaxin-pathway agents are still competing for traction in heart failure, a space where endpoints and responder populations can swing trial outcomes. The update also frames AstraZeneca’s strategy heading toward late-stage studies. The next question for the program will be whether subgroup signals can be validated and translated into durable outcomes such as hospitalization reduction and survival benefits.